Drug Trial Radar · NCT02113163
PK Study Comparing Metformin Eicosapentaenoate to a Combined Dose of Metformin Hydrochloride and Ethyl Ester EPA
Last checked: Nov 20, 2026Latest source record: May 2, 2022 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
32
Planned (sponsor's estimate)
Start
Mar 2014
Primary completion
Jun 2014
Study completion Jul 2014
Sponsor
- Lead sponsor
- Thetis Pharmaceuticals LLCIndustry
- Sponsor type
- Industry
- First posted
- Apr 14, 2014
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The primary objective of the study is to contrast the pharmacokinetic profiles of metformin and EPA delivered separately as co-administered products (metformin hydrochloride or Glucophage and icosapent ethyl or Vascepa) and together as the solid dose form (metformin eicosapentaenoate or TP-101) under fasted and fed conditions. A secondary objective is to evaluate the safety and tolerability of single and repeat single doses of TP-101.
Conditions
- Diabetes Mellitus, Non-Insulin-Dependent
- Hypertriglyceridemia
Interventions
Metformin EicosapentaenoateDrug
Metformin HCl and VascepaDrug
Primary outcomes
What the sponsor says the trial is designed to measure.
- AUC following single and repeat single oral administration of metformin eicosapentaenoate, metformin hydrochloride and VascepaTime frame: PK samples at 0, 0.5, 1, 2, 4, 8, and 12 hours following drug administration
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Pennington Biomedical Research Center
Baton Rouge, Louisiana
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.